Observing how congenital myasthenic syndromes affect patients over time
Official title: A Single Center Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic Syndromes
Run by National Institutes of Health Clinical Center (CC) · NCT06630650 · Data updated 2026-11-12
This study is tracking how congenital myasthenic syndromes affect people over five years to better understand the condition and help improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Months to 99 Years |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | May 12, 2025 |
| Main results expected | December 2, 2042 |
| Study ends | December 2, 2044 |
| Registry record updated | August 13, 2026 |
| Trial ID | NCT06630650 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged six months or older with genetically confirmed congenital myasthenic syndromes.
✕Probably not a fit
Patients without a confirmed genetic diagnosis of congenital myasthenic syndromes may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to understand the natural history of congenital myasthenic syndromes (CMS) by following participants over a five-year period. Individuals aged six months and older with genetically confirmed CMS will undergo a series of tests, including physical exams, heart and lung function assessments, and muscle ultrasounds. The study focuses on DOK7 and COLQ-related CMSs, aiming to characterize clinical manifestations and validate outcome measures for future clinical trials. Participants will have up to seven visits, allowing researchers to track changes in physical strength, performance, and disease severity.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of congenital myasthenic syndromes, enhancing patient care.
How similar studies have gone: While studies on congenital myasthenic syndromes are limited, similar observational studies have provided valuable insights into rare neuromuscular disorders.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged \>= 6 months of age * Clinically stable as evidenced by medical record review and remote screening questionnaire * Genetically confirmed congenital myasthenic syndrome (pathogenic or likely pathogenic variants identified by CLIA testing in an established CMS-related gene including but not limited to DOK7, COLQ, CHRNE, RAPSN, CHAT, GFPT1, DPAGT1 OR pathogenic/likely pathogenic variant in combination with a variant of uncertain significance (VUS) AND additional clinical supporting evidence of CMS). * Agreement to adhere to Lifestyle Considerations throughout study duration * Ability of subject to understand and the willingness to provide informed consent (\>=18 years of age) and assent (\>=7 years of age). EXCLUSION CRITERIA: * Received gene transfer therapy * Pregnant women (prior to enrollment) * Ongoing medical condition or medication use that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study or safety of the subject.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Christopher Grunseich, M.D. — National Institute of Neurological Disorders and Stroke (NINDS)
- Study coordinator: Dana L Macdonald
- Email: dana.macdonald@nih.gov
- Phone: (301) 594-1090
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
VLCPUFA-rich fish oil and standard DHA oil: who reaches a higher omega-3 index?
This study tests whether VLCPUFA-rich fish oil raises the blood omega-3 index more than a standard DHA-rich fish oil in healthy adults aged 18–60.
-
Blood biomarkers for immune-related neuropsychiatric conditions
This study tests whether blood biomarkers can help identify neuropsychiatric disorders that may be linked to the immune system in people of any age.
-
First-in-human imaging of PDE4D with [11C]JMJ-129-d2 in healthy volunteers
A new PET tracer called [11C]JMJ-129-d2 is being tested in healthy adults to see if it safely and reliably images the brain’s PDE4D enzyme and to measure how the tracer distributes in the body.
-
Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people
This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.
-
Augmenting Parent Management Training with a Smartphone Tool
This study tests whether adding a smartphone app to parent management training helps reduce irritability and temper outbursts in kids aged 8–13 with disruptive behavior disorders.
-
How healthy adults look at faces and other images with their eyes
This study tests how healthy adults direct their gaze and pay attention to visual images, including faces, to see how basic visual features influence eye movements.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.